$644.56
Value $18.3B
MEDP and MRK stock compared: price, dividend, valuation and results, from SEC filings.
$644.56
Value $18.3B
$134.13
Value $332B
Medpace (MEDP) has a market value of $18.3B and Merck & Company (MRK) $332B. Over the last year, with dividends, MEDP moved +9.2% and MRK +43.2%. The P/E is 35.3 for MEDP and 135.2 for MRK. Dividend yield: MEDP none, MRK 2.53%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
MEDP$18.3B
MRK$332B
MRK is 18 times MEDP
Revenue, 12 months
MEDP$2.8B
MRK$67.4B
MRK is 24 times MEDP
Net income, 12 months
MEDP$518M
MRK$2.5B
MRK is 4.7 times MEDP
Operating margin
MEDP21.4%
MRK–
ROIC
MEDP105.8%
MRK3.9%
101.9 points apart
P/E
MEDP35.3
MRK135.2
MRK is 3.8 times MEDP
Dividend yield
MEDP0.0%
MRK2.5%
2.5 points apart
5-year return
MEDP+184.9%
MRK+88.1%
96.8 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
MEDP+184.9%
MRK+88.1%
| Period | MEDPWith dividends | MRKWith dividends |
|---|---|---|
| 1 year since November 18, 2025 | +9.2%Price +9.2% | +43.2%Price +39.1% |
| 3 years since November 17, 2023 | +135.2%+33.0% a yearPrice +135.2% | +44.4%+13.0% a yearPrice +31.8% |
| 5 years since November 18, 2021 | +184.9%+23.3% a yearPrice +184.9% | +88.1%+13.5% a yearPrice +61.5% |
| 10 years since November 21, 2016 | +1,693.4%+33.5% a yearPrice +1,693.4% | +206.1%+11.8% a yearPrice +125.6% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
MEDPMedpaceMRKMerck & Company
| Price | $644.56 | $134.13 |
|---|---|---|
| Market value | $18.3B | $332B |
| Enterprise value (EV) | $17.6B | $376B |
| P/E | 35.3 | 135.2 |
| P/E, 5-year median | 34.5 | 14.8 |
| P/B | 31.3 | 7.4 |
| EV/EBIT | 29.0 | 78.9 |
| Free cash flow yield | 3.7% | 4.5% |
| Revenue, 12 months | $2.8B | $67.4B |
|---|---|---|
| Net income, 12 months | $518M | $2.5B |
| Free cash flow, 12 months | $668M | $14.7B |
| Earnings per share, 12 months | $18.01 | $0.98 |
| Revenue growth, year on year | 20.0% | 1.3% |
| Revenue growth a year, past | +22.3%over 5 years | +9.4%over 5 years |
| EPS growth a year, past | +31.8%over 5 years | +21.2%over 5 years |
| Gross margin | – | 71.8% |
|---|---|---|
| Operating margin | 21.4% | – |
| Net margin | 18.2% | 3.6% |
| ROIC | 105.8% | 3.9% |
| ROE | 109.3% | 5.2% |
| Cash | $705M | $9.7B |
|---|---|---|
| Total debt | $171M | $53.8B |
| Net debt / EBITDA | -1.1 | 5.7 |
| Interest cover | – | 2.4× |
| Dividend yield | – | 2.5% |
|---|---|---|
| Dividend per share, 12 months | – | $3.40 |
| Dividend growth a year, past | – | +5.8%over 5 years |
| Buyback yield | 5.0% | 1.5% |
| Shareholder yield | 5.0% | 4.1% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Merck & Company ($332B) is about 18.1 times Medpace ($18.3B), at today's prices.
Since November 21, 2016, MEDP's price moved +1,693.4% and MRK's +125.6%. With dividends: MEDP +1,693.4% (+33.5% a year), MRK +206.1% (+11.8% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Medpace and 2.53% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.
At today's price, the P/E is 35.3 for MEDP and 135.2 for MRK. The median of the last five years was 34.5 and 14.8, which shows where each stands against its own past.
Over the last twelve months, the net margin was 18.2% for Medpace and 3.6% for Merck & Company, and the operating margin 21.4% and –. Revenue was $2.8B and $67.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.